idea [12:<1%. 1 Distribution Extent Not known whether eflornithine crosses the placenta or is distributed into milk. 1 Elimination Metabolism No evidence that eflornithine is metabolized. 1 b Elimination Route Any absorbed eflornithine is excreted in urine as unchanged drug. 1 b Half-life Approximately 8 hours at steady state. 1 b Stability Storage Topical 25 C (may be exposed to 15 30 C); do not freeze. 1 Actions Retards the rate of hair growth. 1 Reduces unwanted hair growth 1 2 8 and may cause hair to become finer and lighter. 2 Precise mechanism of action is unknown. 1 2 8 May inhibit ornithine decarboxylase, which catalyzes biosynthesis of intracellular polyamines required for cell division and differentiation; 1 2 3 4 7 inhibition of cell division and differentiation may reduce rate of hair growth. 1 5 Advice to Patients Importance of providing patient a copy of manufacturer s patient information. 1 8 Eflornithine retards hair growth; it is not a depilatory agent. 1 8 Continue hair removal techniques (e.g., plucking, tweezing, cutting, shaving) as needed. 1 Improvement may be seen within 4 8 weeks of initiating therapy; however, condition may return to pretreatment levels 8 weeks after discontinuing therapy. 1 Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. 1 8 Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs. 1 Importance of informing patients of other important precautionary information. (See Cautions.) Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. Eflornithine Hydrochloride Routes Dosage Forms Strengths Brand Names Manufacturer Topical Cream 13.9% Vaniqa Skinmedica AHFS DI Essentials. Copyright 2017, Selected Revisions July 1, 2005. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. References 1. Bristol-Myers Squibb. Vaniqa (eflornithine hydrochloride 13.9% cream) prescribing information and patient information. Plainsboro, NJ; 2000 Jul 27. 2. Anon. Eflornithine cream for facial hair reduction. Med Lett Drugs Ther . 2000; 42:96. [PubMed 11015161] 3. Paulson YJ, Gilman TM, Heseltine PNR et al. Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Chest . 1992; 101:67-74. [PubMed 1729113] 4. Marion Merrell Dow. Ornidyl (eflornithine hydrochloride for injection concentrate). Kansas City, MO; 1990 Nov. 5. Hynd PI, Nancarrow MJ. Inhibition of polyamine synthesis alters hair follicle function and fiber composition. J Invest Dermatol . 1996; 106:249-53. [PubMed 8601724] 6. Hickman JG, Huber F, Palmisano M. Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair. Curr Med Res Opin . 2001; 16:235-44. [PubMed 11268707] 7. Milord F, Pépin J, Loko L et al. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet . 1992; 340:652-55. [PubMed 1355219] 8. Bristol-Myers Squibb, Plainsboro, NJ; personal communication. a. Women First HealthCare. Vaniqa (eflornithine hydrochloride) cream 13.9%, prescribing information and patient information. San Diego, CA; 2002 Sep. b. Malhotra B, Noveck R, Behr D et al. Percutaneous absorption and pharmacokinetics of eflornithine HCL 13.9% cream in women with unwanted facial hair. J Clin Pharmacol . 2001; 41:972-8. [PubMed 11549102] Next Pregnancy Warnings Print this page Add to My Med List More about eflornithine topical Side Effects During Pregnancy Dosage Information Support Group En Español 58 Reviews Add your own review/rating Drug class: miscellaneous topical agents Consumer resources Eflornithine topical ... +3 more Professional resources Other brands: Vaniqa Related treatment guides Hirsutism> ] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class Miscellaneous topical agents Related Drugs Hirsutism spironolactone , Aldactone , Vaniqa , flutamide , Eulexin , More... Eflornithine topical Rating 58 User Reviews 8.1 /10 58 User Reviews 8.1 Rate it! to steer
trudging away Eflornithine go along with
EmoticonEmoticon